caa a22 4500 605490317 CHVBK 20210128100504.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0681-7 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0681-7 Prostate-specific antigen measured 3months after radical prostatectomy as a new predictor of biochemical recurrence [Elektronische Daten] [Hitoshi Inoue, Kensaku Nishimura, Seiji Yamaguchi, Norio Nonomura, Tsuneo Hara] Background: This study was undertaken to investigate if the prostate-specific antigen (PSA) level measured 3months after radical prostatectomy (RP) is a predictor of biochemical recurrence (BCR)-free survival. Methods: We retrospectively reviewed the clinicopathologic data of 174 patients with a follow-up of at least 3years after RP for clinically localized prostate cancer. None of the patients received neoadjuvant/adjuvant therapy. Subjects were categorized according to PSA level 3months after RP (3M-PSA): <0.010ng/mL (group 1; n=119) or 0.010-0.100ng/mL (group 2; n=55). BCR was defined as two consecutive rises in PSA level ≥0.2ng/mL. Results: At a median follow-up of 69.5months (range 36-113months), 32 (18.4%) patients experienced BCR. The median time to BCR was 16months (range 4-98months) after RP. The 5-year BCR-free survival rate was 92.6 and 57.4% in groups 1 and 2, respectively. Patients in group 1 had a significantly higher BCR-free survival rate than those in group 2 (log-rank P<0.001). According to the Cox proportional hazards model, patients with a 3M-PSA level of <0.010ng/mL were at lower risk for BCR (P<0.001), along with pathologic Gleason sum 6 (P=0.028). PSA nadir level after RP was also a risk factor for BCR (log-rank P<0.001). Area under the receiver operating characteristic curve for 3M-PSA to predict BCR was almost equivalent to that for the PSA nadir level (0.855 vs. 0.849). Conclusions: 3M-PSA is an independent predictor of BCR-free survival. Our findings might be used for a risk-adjusted follow-up protocol. Japan Society of Clinical Oncology, 2014 Prostate cancer nationallicence Prostate-specific antigen nationallicence Radical prostatectomy nationallicence Predictor nationallicence Biochemical recurrence nationallicence Inoue Hitoshi Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan aut Nishimura Kensaku Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan aut Yamaguchi Seiji Department of Urology, Osaka General Medical Center, Osaka, Japan aut Nonomura Norio Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan aut Hara Tsuneo Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 171-175 1341-9625 20:1<171 2015 20 10147 https://doi.org/10.1007/s10147-014-0681-7 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0681-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Inoue Hitoshi Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan aut NATIONALLICENCE 700 1- Nishimura Kensaku Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan aut NATIONALLICENCE 700 1- Yamaguchi Seiji Department of Urology, Osaka General Medical Center, Osaka, Japan aut NATIONALLICENCE 700 1- Nonomura Norio Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Hara Tsuneo Department of Urology, Ikeda Municipal Hospital, 3-1-18 Jonan, 563-8510, Ikeda, Osaka, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 171-175 1341-9625 20:1<171 2015 20 10147